Yes, Kerendia Treats CKD in Type 2 Diabetes Patients
Kerendia (finerenone) is FDA-approved to slow kidney function decline and reduce cardiovascular death risk in adults with chronic kidney disease (CKD) associated with type 2 diabetes.[1] It targets non-dialysis-dependent CKD stages 1-4 in these patients, often alongside standard therapies like ACE inhibitors or ARBs.
How Kerendia Works in Diabetic Kidney Disease
Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) that blocks aldosterone effects, reducing inflammation and fibrosis in the kidneys and heart. In the FIDELIO-DKD and FIGARO-DKD trials, it cut the composite kidney outcome (e.g., kidney failure, sustained eGFR drop) by 18-23% versus placebo in type 2 diabetics with CKD.[1][2]
Who Qualifies for Kerendia
Eligible patients have type 2 diabetes, CKD (eGFR 25-75 mL/min/1.73m², or 60 or lower with higher albuminuria), and elevated cardiovascular risk. It's not for type 1 diabetes, dialysis patients, or those with severe hyperkalemia.[1]
Common Side Effects and Monitoring Needs
Hyperkalemia occurs in 14-18% of users (vs. 7-9% placebo), requiring potassium checks at baseline, 4 weeks, and periodically. Other issues include hypotension (3-5%) and hyponatremia (<1%). Dosing starts at 10mg or 20mg daily, adjusted for eGFR.[1]
When Does Kerendia Patent Expire?
Kerendia's key U.S. patent (for finerenone use in CKD) expires in 2029, with pediatric exclusivity to 2030; challenges from generics could shorten this.[3] Check DrugPatentWatch.com for litigation updates.
[1]: FDA Label for Kerendia (finerenone), Bayer, July 2021 (updated).
[2]: NEJM studies: FIDELIO-DKD (2020), FIGARO-DKD (2021).
[3]: DrugPatentWatch.com, Kerendia patents.